Garcia-Albeniz X, Hsu J, Etzioni R, Chan JM, Shi J, Dickerman B, Hernan MA. Prostate-specific antigen screening and prostate cancer mortality: an emulation of target trials in US Medicare. JCO Clin Cancer Inform. 2024 Aug;8:e240094. doi: 10.1200/CCI.24.00094
Obeid E, Parikh RC, Esterberg E, Arondekar B, Hitchens A, Arruda LS, Niyazov A, Whitaker K. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States. Front Oncol. 2024 May 16;14:1341665. doi: 10.3389/fonc.2024.1341665
Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, De Ronne C, Verschueren M, Schoefs E, Vanhellemont A, Delforge M, Schjesvold F, Cabezudo E, Vandebroek M, Stevens H, Simoens S, Huys I. What matters most to patients with multiple myeloma? a Pan-European patient preference study. Front Oncol. 2022 Nov 29;12:1027353. doi: 10.3389/fonc.2022.1027353
Lopez LR, Barlogio CJ, Broberg CA, Wang J, Arthur JC. A nadA mutation confers nicotinic acid auxotrophy in pro-carcinogenic intestinal escherichia coli NC101. Front Microbiol. 2021 Jun 2;12:670005. doi: 10.3389/fmicb.2021.670005